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CORRESPONDENCE
Generic medicines are not
substandard medicines
Sir—Carol  Adelman  and  Jeremiah
Norris (Dec 22/29, p 2174),
1 who work
for  the  industry-funded  Hudson
Institute, advocate the use of patented
drugs,  pointing  to  what  they  say  are
risks  associated  with  generic  drugs.
They  confuse  generic  drugs  with  old,
substandard,  ineffective,  and
counterfeit drugs.
Generic  does  not  mean  old.  The
1996  World  Trade  Organisation
(WTO)  Agreements  mandate  all
member  countries  to  provide  20-year
patent protection for medicines. Before
that  date,  however,  many  countries
(including  Spain,  Finland,  and  India)
thought of medicines as too important
to  subject  to  market  monopolies  and
exempted them from patentability. All
drugs  in  these  countries  could,
therefore, be generic. This situation is
still  true  for  countries  that  have  not
implemented the WTO Agreements.
Drug quality is important. Médecins
sans Frontières advocates for improved
quality  surveillance.  We  support
WHO’s  efforts  to  assist  countries  by
assessing  quality  of  many  technically
complicated  pharmaceutical  products,
including the prequalification of generic
antiretroviral suppliers.
Generic  does  not,  however,  mean
unsafe  or  ineffective,  just  as  patented
does  not  necessarily  mean  safe  and
effective. Most medicines on the WHO
Model Essential Drugs List are generic.
Many vital patented drugs are excluded
from the list because they do not meet
the  affordability  criteria.  For  drug
resistance  and  treatment  adherence,
generic  companies  may  be  in  a  better
position to provide effective treatments
by producing certain combinations and
formulations  that  brand  companies
cannot or will not produce.
2
Counterfeiting  is  a  separate  issue
referring  to  the  deliberate  and
fraudulent mislabelling of medicines for
identity  or  source.  Counterfeiting
mostly  concerns  expensive  branded
drugs.
The  only  consistent  practical
difference  between  generic  and
patented  drugs  is  their  price.  Because
market  monopolies  drive  prices  up,
generic agents are less expensive. The
price of patented drugs is a barrier to
access to medicines for many diseases
that  are  common  in  less-developed
countries.  Access  to  AIDS  medicines
has  increased  strikingly  in  some
countries  through  the  use  of  generic
drugs.
3 Affordable, high-quality, generic
alternatives  exist  for  many  diseases
causing  substantial  mortality  and
morbidity  in  the  less-developed  world
(eg,  trachoma,  kala-azar,  and
cryptococcal  meningitis
4),  which,  if 
the  right  prohealth  policies  are
implemented, could be used to increase
access in all countries in need.
Introduction  of  market  competition
through  parallel  importation  (com-
petition  between  branded  drugs)  or
compulsory  licence  (competition  with
generic drugs) is an important way to
lower drug prices in a sustainable way.
The Brazilian government, for example,
has  used  extensive  generic  production
and the threat of compulsory licensing
to reduce the price of AIDS drugs. The
declaration  at  the  WTO  meeting  in
Doha in November, 2001,
5 which states
clearly  that  countries  can  rightfully
overcome  patents,  should  encourage
other countries to implement and use a
compulsory  licensing  system  for
expensive drugs they deem essential in
their health-care system.
Drug  quality,  safety,  and  effective-
ness are matters of great concern. So is
lack of access to essential medicines in
the developing world. It is essential for
millions of people that the latter is not
limited by confusing and bias concerns
over the former.
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policy diverges from that of Médecins
Sans Frontières, which advocates using
only  the  cheapest  generic  drugs  from
developing countries such as India. 
Second, we do not confuse generic
drugs  with  “old,  substandard,  in-
effective,  and  counterfeit  drugs”,  as
Ford and ‘t Hoen say. Unfortunately,
the chances of getting such drugs are
much  higher  when  searching  for  the
cheapest drugs in developing countries.
The high prevalence of these dangerous
drugs in Nigeria and southeast Asia is
alarming, as noted by other scientists:
“The most probable cause of the poor
quality of drugs is absence of adequate
quality assurance during manufacture.
Substandard  drugs  sold  in  the
pharmacies of less-developed countries
could  contribute  to  global  microbial
resistance  and  therapeutic  failure  of
infectious diseases.”
1
Our main point is the same as that
made by Li Wan Po
2 from the Centre
for  Evidence-Based  Pharmacotherapy,
that price should not be the only basis
by  which  a  supplier  is  chosen.
Countries  should  buy  high-quality
generics,  high-quality  patented  drugs,
or both. For the safety of their citizens,
however, they should not buy only the
cheapest  drugs  from  developing
countries.
While  older  generic  drugs  can
certainly  be  appropriate,  WHO  has
voiced some concerns. They note that
the increasing prevalence of strains of
common  pathogenic  bacteria  resistant
to  widely  available,  relatively  cheap
antimicrobials  in  the  Essential  Drug
List  is  dangerously  eroding  their
effectiveness.
3 Rubin
4 has noted that it
is  not  the  striking  episode  of  an
epidemic  due  to  antibiotic-resistant
organisms that is at issue; rather, it is
the  growing  problem  of  endemic
infection due to organisms resistant to
formulary drugs.
Focusing on patents and compulsory
licensing,  as  do  Ford  and  ‘t  Hoen,
ignores  the  many  real  barriers  to
treating  infectious  diseases  in  poor
countries—poverty,  corruption,  and
lack of health-care infrastructure. In a
study of 53 African countries, patents
and patent law were not seen as a major
barrier  to  treatment  access,  and  the
researchers  noted  that  the  option  to
patent antiretroviral drugs in Africa has
frequently gone unexercised.
5 If patents
and  prices  were  the  most  important
barrier  to  improved  health  care  in
developing  countries,  why  has
tuberculosis not been treated and cured
with  the  low-priced,  quality  generic
drugs  that  have  been  available  for
years?
To assert, as Ford and ‘t Hoen do,
that  quality,  safety,  and  effectiveness
Authors’ reply
Sir—It  is  discouraging  that  Nathan
Ford and Ellen ‘t Hoen divert attention
from the merits of science to disparage
our institutional affiliation. More than
80%  of  Hudson  Institute  funding
comes  from  individuals,  foundations,
and  governments.  We  do  not  cast
aspersions over the funding sources of
Médecins Sans Frontières to engage in
scientific debate with them.
First, we do not advocate use of only
patented  drugs.  We  do  advocate
standard practice of using both generic
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are not issues in the access to medicines
debate is wrong and a disservice to the
people whom the Hudson Institute and
Médecins Sans Frontières wish to help.
*Carol Adelman, Jeremiah Norris
Hudson Institute, Washington, DC 20036, USA
1 Taylor RB, Shakoor O, Behrens RH, et al.
Pharmacopoeial quality of drugs supplied by
Nigerian pharmacies. Lancet 2001; 357:
1933–36.
2 Li Wan Po A. Too much, too little, or none
at all: dealing with substandard and fake
drugs. Lancet 2001; 357: 1904.
3 Implementation of WHO’s revised drug
strategy: safety and efficacy of
pharmaceutical products—forty-fifth World
Health Assembly. Geneva: WHO, March
18, 1992.
4 Rubin RH. A comparative analysis of some
drugs on the EDL. In: A discussion paper
on the issues raised by a WHO resolution
vis-à-vis US trade interests. Boston, MA:
Harvard Medical International, Oct 3, 1996.
5 Attaran A, Gillespie-White L. Do patents
for antiretroviral drugs constrain access to
AIDS treatment in Africa? JAMA 2001;
286: 1886–92.
the  study  was  haphazard,  and  since
1997  all  children  have  received
postexposure  prophylaxis  (Sebastian
van As, personal communication). 
In  consensual  sex  in  developed
countries,  the  average  risk  of  trans-
mission  per  contact  for  unprotected
receptive anal intercourse with an HIV-
positive  man  is  around  5%;  for
unprotected  receptive  vaginal  inter-
course this risk is less than 1%.
5 The
risk  after  rape  is  much  greater  and
although  multiple  penetrations  by
multiple  perpetrators,  dry  sex,  the
presence of other sexually transmitted
infections,  and  the  occurrence  of
perineal  injury  increase  the  risk  after
rape, a low seroconversion rate is still
consistent  with  a  high  HIV-positivity
rate among perpetrators. The fact that
few  perpetrators  admit  that  the  myth
motivated  their  actions  is  hardly
surprising  given  that  around  63%  of
traced offenders are not even tried for
their crimes in South Africa and only
7% receive a prison sentence.
4
We agree with Jewkes and colleagues
that rape in South Africa occurs in the
context of a society inured to very high
levels  of  violence,  with  fractured
families and communities and extreme
inequality between the sexes. However,
the high level of poverty to which they
correctly refer as a contributory factor
cannot be divorced from high levels of
ignorance  and  illiteracy,  which  we
believe  potentiate  dangerous  beliefs
and  traditions.  We  concur  that  the
virgin  cleansing  myth  is  not  the  only
motivation behind the appalling levels
of rape in South Africa, but we believe
it is important. We add our voices to
that  of  Charlene  Smith,  the  noted
South  African  rape  activist,  who  has
questioned  why  there  is  a  paucity  of
research on this practice or vociferous
advocacy to challenge it.
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Intestinal permeability and
coeliac disease
Sir—Ian Perry and colleagues (Nov 17,
p 1729–30),
1 comment on our July 28
Commentary.
2 We agree with them in
principle  that  there  have  been
important  advances  in  our  knowledge
of  molecular  biology,  especially  in
relation to their interaction with tight
junctions in coeliac disease.
However, our remit was to provide a
Commentary  on  the  report  by
Cummins and colleagues.
3 The original
report  related  to  the  timing  of
improvements  in  intestinal  permeabil-
ity  and  intestinal  morphometry  in
treated  coeliac  disease.  Hence  our 
main  thrust  related  to  intestinal
morphometry, with some reference to
zonulin, and other adhesion molecules.
Our Commentary was not designed to
be an exhaustive review of the subject.
The  use  of  cytokine-regulated
expression  of  adhesion  molecules  and
its  effect  on  the  disruption  of
intercellular junctions provides a useful
insight  into  the  pathophysiology  of 
coeliac  disease,  but  measurement  of
these  molecules  is  currently  of  no
practical use for diagnosis or follow-up
of  coeliac  disease.  By  contrast,  the
intestinal permeability test is a reliable,
practical, outpatient-based test and it is
useful in screening for coeliac disease.
We therefore maintain that the use of
intestinal  permeability  tests  for
intestinal morphometric improvements
in  treated  coeliac  disease  still  provide
useful  insights  into  the  patho-
physiological  events  at  the  mucosal
level.
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Motivation behind infant
rape in South Africa
Sir—Rachel  Jewkes  and  colleagues
(Feb 23, p 711)
1 write that child rape is
not  exotic;  however,  we  aimed  to
highlight  infant  rape  with  associated
perineal  injury.  In  our  practice  in
Johannesburg,  perineal  mutilation  of
infants  (hardly  an  injury  that  fails  to
present  for  medical  treatment)  has
recently emerged as a distinct clinical
entity.
Jewkes  and  colleagues  dispute  the
assertion that the virgin cleansing myth
is  an  important  cause  of  child  sexual
abuse. The idea that sex with a virgin
will  cure  men  of  sexually  transmitted
infection  is  not  new,  nor  exclusively
African. In renaissance Europe, it was
widely  believed  that  syphilis  could  be
cured  by  intercourse  with  a  virgin. 
In  1925,  Samuel  Cameron
2 wrote:
“The disgusting superstition, surviving
amongst  ignorant  and  vicious  men, 
that  contact  with  an  immature  vulva
will  cure  venereal  disease,  is  still
responsible  [for  transmission  of
gonorrhoea] in many cases.” In a South
African  sexual-health  workshop,
reported  by  Jewkes  herself  in  2000,
32·7% of participants believed sex with
a virgin could cure HIV infection. After
14  sessions  of  2–3  h  each,  this  myth
was  still  believed  by  20%  of  the
participants.
3
Jewkes  believes  that  a  1%
seroconversion  rate  in  raped  children
from  Cape  Town
4 disproves  the
cleansing myth because the rate is too
low. This reported rate is falsely low,
since HIV testing in the early years of
DEPARTMENT OF ERROR
Chronic  fatigue  syndrome:  a  step  towards
agreement—A typographical error in paragraph
4 of this Commentary by Christopher Clark and
colleagues  (Jan  12,  p  97)  may  cause  some
confusion. Only four of the six dissenters were
clinicians,  as  described  lower  down  the
paragraph.